CN114767729A - Application of medicinal composition of Qudesheng snake or preparation thereof in preparation of medicines for preventing, relieving, and assisting in treating or treating facial spasm or endogenous wind - Google Patents
Application of medicinal composition of Qudesheng snake or preparation thereof in preparation of medicines for preventing, relieving, and assisting in treating or treating facial spasm or endogenous wind Download PDFInfo
- Publication number
- CN114767729A CN114767729A CN202210573826.1A CN202210573826A CN114767729A CN 114767729 A CN114767729 A CN 114767729A CN 202210573826 A CN202210573826 A CN 202210573826A CN 114767729 A CN114767729 A CN 114767729A
- Authority
- CN
- China
- Prior art keywords
- tablets
- treating
- snake
- formulation
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010063006 Facial spasm Diseases 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 241000270295 Serpentes Species 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 239000000203 mixture Substances 0.000 title claims description 15
- 229940079593 drug Drugs 0.000 title description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 239000003826 tablet Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 239000006189 buccal tablet Substances 0.000 claims description 2
- 239000007910 chewable tablet Substances 0.000 claims description 2
- 239000007891 compressed tablet Substances 0.000 claims description 2
- 239000007919 dispersible tablet Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000007938 effervescent tablet Substances 0.000 claims description 2
- 239000002662 enteric coated tablet Substances 0.000 claims description 2
- 239000007941 film coated tablet Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000012669 liquid formulation Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 239000006190 sub-lingual tablet Substances 0.000 claims description 2
- 239000007940 sugar coated tablet Substances 0.000 claims description 2
- 239000007939 sustained release tablet Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 238000011282 treatment Methods 0.000 description 24
- 230000000694 effects Effects 0.000 description 16
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 238000001467 acupuncture Methods 0.000 description 9
- 230000036461 convulsion Effects 0.000 description 9
- 208000005392 Spasm Diseases 0.000 description 7
- 239000006072 paste Substances 0.000 description 7
- 206010010904 Convulsion Diseases 0.000 description 6
- 210000001367 artery Anatomy 0.000 description 6
- 230000002490 cerebral effect Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 206010028347 Muscle twitching Diseases 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 230000001815 facial effect Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 210000000744 eyelid Anatomy 0.000 description 3
- 210000001097 facial muscle Anatomy 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000001314 paroxysmal effect Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 206010012305 Demyelination Diseases 0.000 description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 208000004078 Snake Bites Diseases 0.000 description 2
- 208000003217 Tetany Diseases 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 210000000256 facial nerve Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000011505 plaster Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000006373 Bell palsy Diseases 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000244987 Daiswa polyphylla Species 0.000 description 1
- 208000004929 Facial Paralysis Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000004095 Hemifacial Spasm Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010029174 Nerve compression Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000131808 Scolopendra Species 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 206010070995 Vascular compression Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 210000001841 basilar artery Anatomy 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 1
- 229960000623 carbamazepine Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 208000014337 facial nerve disease Diseases 0.000 description 1
- 238000003958 fumigation Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 229960005321 mecobalamin Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 210000003388 posterior cerebral artery Anatomy 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/648—Myriapods, e.g. centipedes or millipedes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/65—Amphibians, e.g. toads, frogs, salamanders or newts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
- A61K36/12—Filicopsida or Pteridopsida
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the field of pharmaceutical preparations, in particular to application of a Qudesheng snake pharmaceutical composition or a preparation thereof in preparing a medicament for preventing, relieving, assisting in treating or treating facial spasm or endogenous wind.
Description
Technical Field
The invention relates to the field of pharmaceutical preparations, in particular to a Qudesheng snake pharmaceutical composition or application of a preparation thereof in preparing a medicament for preventing, relieving, assisting in treating or treating facial spasm or endogenous wind.
Background
The facial Spasm (HFS), also known as facial Spasm or Hemifacial Spasm, is manifested as involuntary facial twitching limited to the eyelids, cheeks and corners of the mouth in mild cases, and can extend to the entire facial area in severe cases, with more symptoms occurring on one side. Convulsions are paroxysmal, irregular and of different degrees, and can be aggravated by fatigue, mental stress and voluntary exercise. The onset is mostly from the orbicularis oculi muscle and then involves the entire face. It is commonly seen in middle-aged and elderly people, and women with disease. The HFS is slow in disease incidence and long in disease duration, most of HFS is safe in the process of treating the HFS, the disease does not endanger life in the process of progression, but long-term involuntary twitching of facial muscles can bring certain influence on psychology and social activities of patients, and serious patients can reduce the life quality of the patients.
From the syndrome differentiation theory of traditional Chinese medicine, the facial spasm belongs to endogenous wind. The etiology is quite different from stroke, and the Chinese medical science has thought that all kinds of wind fall dizziness and belong to the liver. Also, the brain is considered by the Chinese medical scientists as the house of spirit, and should be induced by acupuncture to restore consciousness and treat meridians. Clinically, it is a syndrome of excess in origin and predominance of upper-jiao and lower-jiao due to facial spasm, deficiency of both qi and blood and failure of blood to melt body fluids.
The causes of the facial spasm, the western causes of the facial spasm, are mainly researched, and the facial spasm is mainly caused by vascular compression, and also has a statement that intracranial space occupying lesion can also cause the facial spasm, namely secondary facial spasm. In addition, facial spasm is induced by facial paralysis followed by facial neuritis, edema, ischemia, and demyelination of facial nerves. In traditional Chinese medicine, the disease is classified into wind syndrome or facial wind, some of which are also called cytotwitching or eyelid twitching.
Some facial spasm is caused by age problem, hardening of blood vessels crossing nerves, blood pressure increase, demyelination due to long-term nerve compression, etc., so that crosstalk occurs between nerve axons, excitation is changed from efferent to afferent, and a large amount of abnormal potential is accumulated and released, thereby causing facial spasm.
Some patients are idiopathic facial paralysis, and secondary spasms of the affected facial muscles occur after recovery. Among the vascular factors, the posterior lower cerebellar artery and the anterior lower cerebellar artery are the main ones, while the superior cerebellar artery is the second one. It is known that the superior cerebellar artery originates from the junction of the basilar artery and the posterior cerebral artery, and the posterior cerebellar artery and the anterior cerebellar artery have the most constant running, but have relatively large variation, so that a blood vessel loop or ectopic compression is easily formed to the facial nerve. Causing facial spasm.
Clinical understanding and treatment of HFS are different in methods, acupuncture, moxibustion, cupping, bloodletting therapy, traditional Chinese medicine and traditional Chinese medicine fumigation, acupuncture point injection and other methods are adopted in traditional medicine, operation treatment is firstly carried out in western medicine, and then botulinum toxin injection, oral medicine and other treatments are carried out. Although surgical treatments have the unique advantage of being short-lived and fast-acting, they still have risks and side effects; the injection therapy of the medicine has more injection times, slow effect, undesirable treatment effect and high cost. The traditional Chinese medicine acupuncture and moxibustion is matched with traditional Chinese medicines to treat HFS, and has the advantages of definite curative effect, small pain, no influence on normal life, no side effect and the like.
Disclosure of Invention
Therefore, the technical problem to be solved by the invention is to provide a new application of the Qudesheng snake pharmaceutical composition or the preparation thereof in preparing the medicines for preventing, relieving, assisting in treating or treating the facial spasm or endogenous wind.
Therefore, the invention provides the following technical scheme:
the application of the medicinal composition or the preparation of the medicinal composition of the Qudesheng snake in preparing medicaments for preventing, relieving, assisting in treating or treating facial spasm or endogenous wind.
Optionally, the preparation takes the medicinal composition of Quesheng snake as an active component.
Optionally, the formulation further comprises formulation-approved excipients or carriers.
Optionally, the form of the formulation includes a liquid formulation or a solid formulation.
Optionally, the preparation comprises injection, tablet, capsule, oral liquid, granule, pill or paste.
Optionally, the tablet comprises a common compressed tablet, a coated tablet, a sugar-coated tablet, a film-coated tablet, an enteric-coated tablet, an effervescent tablet, a chewable tablet, a multi-layer tablet, a dispersible tablet, a sublingual tablet, a buccal tablet, a solution tablet or a sustained-release tablet; or
The capsule comprises a hard capsule, a soft capsule or an enteric capsule.
The preparation method of the paste comprises the following steps: pulverizing Qudesheng snake medicinal composition into powder, adding solvent, blending into non-flowing paste, and placing on cataplasma.
The technical scheme of the invention has the following advantages:
1. the Qudesheng snake tablet is produced by the independent company of essence pharmaceutical group, and the prescription and process are listed in the state secret (secret level), is a necessary medicine for emergency treatment of departments of Chinese academy of medicine, has the functions of mainly clearing heat, detoxifying, reducing swelling and relieving pain, and is used for treating bite of poisonous snakes and poisonous insects. Researches show that the paris polyphylla in the Jidesheng snake prescription is bitter in taste and cold in nature and enters liver channels, has the effects of clearing heat and removing toxicity, relieving swelling and pain, cooling liver and arresting convulsion, is commonly used for treating furuncle and carbuncle, swollen sore throat, snake and insect bite, traumatic injury, convulsion and tetany, has good effects of cooling liver and purging fire, has good effects on stopping wind and arresting convulsion, and can be used for treating the problems of extreme endogenous wind caused by infantile hand and foot heat, tetany and the like by compatibility of medicines; scolopendra with pungent and warm taste and entering liver meridian has effects of calming endogenous wind and relieving spasm, dredging collaterals and relieving pain, removing toxic substance and resolving hard mass, and can be used for treating stirring of liver wind, spasm and convulsion, infantile convulsion, and apoplexy
Hemiplegia, tetanus, rheumatism, headache, sore and ulcer, scrofula, snake and insect bite. The two medicines have the effects of calming endogenous wind and relieving spasm, can be used for treating facial spasm, have remarkable curative effect on facial spasm or endogenous wind by combining with other medicines in Qudesheng snake medicine on the basis, and can be used for preparing medicines for preventing, relieving and assisting in treating facial spasm or endogenous windA medicament for treating or curing facial spasm or endogenous wind.
Detailed Description
The following examples are provided to further understand the present invention, not to limit the scope of the present invention, but to provide the best mode, not to limit the content and the protection scope of the present invention, and any product similar or similar to the present invention, which is obtained by combining the present invention with other prior art features, falls within the protection scope of the present invention.
The examples do not show the specific experimental steps or conditions, and can be performed according to the conventional experimental steps described in the literature in the field. The reagents or instruments used are conventional reagent products which are commercially available, and manufacturers are not indicated.
The Qudesheng snake tablets in the following experimental examples were provided by essence pharmaceutical group, Inc.
Example pastes
Pulverizing Qudesheng snake tablet into powder, adding yellow wine, blending into non-flowing paste, and placing on cataplasma.
Experimental example 1 clinical study
1.1 Observation grouping
The 60 facial spasm patients recorded in the clinical observation are strictly screened according to the diagnosis and inclusion standards of diseases, the random digital table method is used for coding, the subjects meeting the diagnosis standards need to sign an informed consent before entering the test, and the subjects are grouped according to the random codes and are divided into 30 cases of treatment groups and 30 cases of control groups. Wherein 30 patients in the treatment group take Quidesheng snake tablets orally (6 tablets each time, twice a day, one month as a treatment course) and combine the traditional acupuncture method, and 30 patients in the control group only adopt the traditional acupuncture method (Ashi point is used as main point, acupuncture local facial points such as Zanzhu point, Sibai point, Yingxiang point and Di cang point), and are analyzed statistically, and the patients have no significant difference (P >0.05) in the aspects of age, sex and course of disease, and the like, which shows comparability. For general details of the treatment groups and the control group, see the table below.
TABLE 1 sex ratio of two groups of patients
Note: warp X2Test, P ═ 0.795, (P)>0.05), suggesting that the two groups of cases have no statistical difference in sex and are comparable.
TABLE 2 age comparison of two groups of patients
Note: by t test, P is 0.154, (P >0.05), and the two groups have no significant difference in age and are comparable.
TABLE 3 comparison of the course of disease between two groups of patients
Note: statistical comparison showed that P ═ 0.647, (P >0.05), suggesting that the two groups of cases were not statistically different in disease course and were comparable.
1.2 Observation of results
The facial spasm is classified into 0-4 grades according to Cohen and Albert standards, the score is 0-4, and the higher the score is, the more severe the spasm is. After treatment, the grading scores of spasm of the two groups are reduced in different degrees, and the curative effect of the treatment group is obviously superior to that of the control group.
TABLE 4 comparison of the spasticity grades of the two groups
Note: compared with the same group before treatment1)(P<0.05); compared with the control group after the treatment,2)(P<0.05)。
the total effective rate of the treatment group is 83.33%, the total effective rate of the control group is 46.67%, and the comparison difference of the two groups is proved to have statistical significance (P is less than 0.05) through statistical analysis, which shows that the treatment group has better curative effect than the control group, and the details are shown in Table 5.
TABLE 5 comparison of clinical efficacy of two groups of facial spasm patients
Note: compare to control 1) (P < 0.05).
Experimental example 2 clinical cases
Case 1: li Shi, 55 years old, female, had no obvious cause of right canthus twitching, no pain, no tinnitus before three years. It is paroxysmal, aggravated when tired and tired, and relieved when resting. The accumulated right mouth corner is twitched about two years ago, and twitched together with the canthus, the oral carbamazepine is given, the effect is not good after taking, in order to further diagnose and treat, the effect is obvious after the traditional Chinese medicine oral treatment (6 Qudesheng snake tablets are taken orally each time, twice a day, and one month is a treatment course) is given in combination with acupuncture massage treatment, the facial twitch symptom lasting for two years after the treatment is controlled, and the treatment has not been done again until now.
Case 2: aged 45 years old, women, who have five years of inquiry due to involuntary twitching in the right side of the face. In 2016, the right eyelid is not automatically jumped, and at the moment, no attention is paid, the disease condition develops after half a year, the right eyelid is paroxysmal twitching, the time and the frequency of attack are different every day, the disease condition gradually worsens after two years, the muscles of the right corners of the mouth and the cheeks are also twitched, the emotion is aggravated when the patient is nervous, no definite diagnosis is given in local hospitals in 2018, and the oral mecobalamin tablet is not improved for two months. In 2019, for effective treatment, the effect is obvious after the traditional Chinese medicine oral treatment (Qudesheng snake tablets are orally taken 6 tablets each time, twice a day and one month as a treatment course) is matched with acupuncture and massage treatment, the back twitch symptom is effectively relieved, and the twitch of muscles of corners of the mouth and cheeks is not repeated until now.
Case 3: liu Yi, women, 60 years old, and 6 months and 18 days in 2008, facial muscle spasm is more than one year, and can jump when there is no time, perhaps several times a day, perhaps no jump a day, then plaster (Jidesheng snake tablet is ground into fine powder, and a small amount of yellow wine is added to blend into a non-flowing paste, and the paste is placed on a cataplasm and applied to the affected part), one plaster is used for 10 days, and 4 plasters are used for curing.
It should be understood that the above examples are only for clarity of illustration and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications derived therefrom are intended to be within the scope of the invention.
Claims (7)
1. The application of the Qudesheng snake medicine composition or the preparation thereof in preparing the medicine for preventing, relieving, assisting in treating or treating the facial spasm or endogenous wind.
2. The use as claimed in claim 1, wherein the formulation is a pharmaceutical composition of Queshen snake as an active ingredient.
3. Use according to claim 2, wherein the formulation further comprises a formulation-approved excipient or carrier.
4. Use according to claim 3 or 4, wherein the formulation is in a form comprising a liquid formulation or a solid formulation.
5. Use according to any one of claims 1 to 4, wherein the formulation comprises an injection, a tablet, a capsule, an oral liquid, a granule, a pill or an ointment.
6. Use according to claim 5, wherein the tablets comprise compressed tablets, coated tablets, sugar-coated tablets, film-coated tablets, enteric-coated tablets, effervescent tablets, chewable tablets, multilayer tablets, dispersible tablets, sublingual tablets, buccal tablets, solution tablets or sustained-release tablets; or
The capsule comprises a hard capsule, a soft capsule or an enteric capsule.
7. Use according to claim 5 or 6, characterized in that said paste is prepared by a process comprising: pulverizing Qudesheng snake medicinal composition into powder, adding solvent, blending into non-flowing paste, and placing on cataplasma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210573826.1A CN114767729A (en) | 2022-05-24 | 2022-05-24 | Application of medicinal composition of Qudesheng snake or preparation thereof in preparation of medicines for preventing, relieving, and assisting in treating or treating facial spasm or endogenous wind |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210573826.1A CN114767729A (en) | 2022-05-24 | 2022-05-24 | Application of medicinal composition of Qudesheng snake or preparation thereof in preparation of medicines for preventing, relieving, and assisting in treating or treating facial spasm or endogenous wind |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114767729A true CN114767729A (en) | 2022-07-22 |
Family
ID=82407931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210573826.1A Pending CN114767729A (en) | 2022-05-24 | 2022-05-24 | Application of medicinal composition of Qudesheng snake or preparation thereof in preparation of medicines for preventing, relieving, and assisting in treating or treating facial spasm or endogenous wind |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114767729A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116870090A (en) * | 2023-08-04 | 2023-10-13 | 精华制药集团股份有限公司 | Application of Jide Sheng medicine composition or preparation thereof in preparation of medicine for relieving, auxiliary treating or treating diabetic foot |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1362206A (en) * | 2001-01-08 | 2002-08-07 | 杨孟君 | Nano Jidesheng sanke bite treating medicine and its preparation |
| CN101269133A (en) * | 2007-03-23 | 2008-09-24 | 河北以岭医药研究院有限公司 | Application of Chinese medicinal composition in preparing medicament for treating facial spasm |
-
2022
- 2022-05-24 CN CN202210573826.1A patent/CN114767729A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1362206A (en) * | 2001-01-08 | 2002-08-07 | 杨孟君 | Nano Jidesheng sanke bite treating medicine and its preparation |
| CN101269133A (en) * | 2007-03-23 | 2008-09-24 | 河北以岭医药研究院有限公司 | Application of Chinese medicinal composition in preparing medicament for treating facial spasm |
Non-Patent Citations (2)
| Title |
|---|
| 梁传亭: "《中药理性撰要》", 30 April 2019, 中医古籍出版社 * |
| 陈斌: "《病毒性皮肤病用药与食疗》", 31 October 2013, 金盾出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116870090A (en) * | 2023-08-04 | 2023-10-13 | 精华制药集团股份有限公司 | Application of Jide Sheng medicine composition or preparation thereof in preparation of medicine for relieving, auxiliary treating or treating diabetic foot |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL170157A (en) | Botulinum toxin for treatment of sinusitis related chronic facial pain and headache | |
| WO2008031322A1 (en) | Application of acetylcholine esterase inhibitor medication of leonurus extractive as cholinomimetic | |
| CN114010751B9 (en) | Traditional Chinese medicine composition for preventing and treating cancer-induced fatigue | |
| CN114767729A (en) | Application of medicinal composition of Qudesheng snake or preparation thereof in preparation of medicines for preventing, relieving, and assisting in treating or treating facial spasm or endogenous wind | |
| CN105232976B (en) | Composition for preventing or/and treating sub-health | |
| CN1965996A (en) | Preparation method of Chinese medicinal capsule for treating apoplexy | |
| CN110179961B (en) | Pharmaceutical composition, preparation method and application thereof | |
| CN105106440B (en) | A kind of Chinese medicine composition for the treatment of headache and dizzy after lumbar anesthesia | |
| CN108451951A (en) | A kind of new drug for treating neurogenic disease | |
| CN107854620B (en) | Traditional Chinese medicine composition for improving cognitive dysfunction after brain injury and application thereof | |
| CN101342208B (en) | Chinese medicinal composition for treating coronary disease, stenocardia, arrhythmia and preparation method thereof | |
| CN101301447B (en) | Chinese medicinal composition for treating epilepsy | |
| RHINOL | Observational study to assess the effect of Audistim® on the quality of life of patients presenting with chronic tinnitus | |
| CN1723933A (en) | Traditional Chinese medicine capsule for treating application, and its prodn. method | |
| CN109876131A (en) | A kind of awake Chinese medicine of rush and preparation method thereof for treating craniocerebral injury stupor | |
| CN108498615A (en) | A kind of Chinese herb medicine eye health-care patch and preparation method thereof improving eyes based on nitric oxide principle | |
| CN103990044B (en) | A kind of Chinese medicine composition for treating epilepsy, its preparation method, preparation and application | |
| CN108478567A (en) | Novel pharmaceutical formulation | |
| CN114617939B (en) | Traditional Chinese medicine preparation for treating ischemic cerebral apoplexy | |
| CN107029189A (en) | Treat the Chinese medicine of coronary heart disease | |
| CN101579419B (en) | Medicinal liquor for treating hyperosteogeny | |
| CN107929338A (en) | The new application of Pien Tze Huang and its preparation in the medicine for preparing treatment post-herpetic neuralgia | |
| CN108578549B (en) | Medicine for treating acne and application thereof | |
| CN207125908U (en) | For coronary disease and angina pectoris paster | |
| CN117180353A (en) | A Chinese medicinal composition for treating diabetes, and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220722 |